Drugs / VRC-ZKADNA090-00-VP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02996461 | Dec 2016 → Sep 2019 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03110770 | Mar 2017 → Oct 2019 | Zika virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-ZKADNA090-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02996461 ↗ |
| Known as | VRC 5283 | “VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins...” NCT03110770 ↗ |
| Modality | Vaccine | “ZIKVwt DNA vaccine” NCT02996461 ↗ |
| Route | Intramuscular | “full dose by one intramuscular (IM) injection with needle and syringe” NCT02996461 ↗ |